Scholarlink

Background <p>Necrotizing pneumonia is a life-threatening complication of community-acquired pneumonia managed in an intensive care setting with a multitude of diagnostic modalities and numerous therapeutic interventions. <i>Pseudomonas aeruginosa</i> remains an extremely uncommon organism known to cause necrotizing pneumonia, and of the cases reported, are almost entirely found in immunocompromised hosts. </p> Case details <p>Here, we report a case of Pseudomonas aeruginosa community-acquired necrotizing pneumonia in a host receiving adalimumab therapy that ultimately was not able to be healed despite targeted antibiotics. </p> Conclusion <p>Adalimumab is known to immunosuppress patients and increase risk of tuberculosis and fungal disease, but have unclear associations with other infections. This case exemplifies a rare encounter of <i>Pseudomonas aeruginosa</i> necrotizing pneumonia in a patient on adalimumab therapy contracted through the community. Treatment of necrotizing pneumonia in patients on adalimumab therapy does not differ significantly from other cases of non-adalimumab associated necrotizing pneumonia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A rare case of community-acquired necrotizing pneumonia in a patient treated with adalimumab therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月13日

查看全文
  • Branavan Ragunanthan,
  • Bachar Botrus,
  • Bibek Shrestha,
  • Jason Kim,
  • Hend Elsaghir,
  • Caitlyn Hollingshead,
  • Fadi Safi

摘要

Background

Necrotizing pneumonia is a life-threatening complication of community-acquired pneumonia managed in an intensive care setting with a multitude of diagnostic modalities and numerous therapeutic interventions. Pseudomonas aeruginosa remains an extremely uncommon organism known to cause necrotizing pneumonia, and of the cases reported, are almost entirely found in immunocompromised hosts.

Case details

Here, we report a case of Pseudomonas aeruginosa community-acquired necrotizing pneumonia in a host receiving adalimumab therapy that ultimately was not able to be healed despite targeted antibiotics.

Conclusion

Adalimumab is known to immunosuppress patients and increase risk of tuberculosis and fungal disease, but have unclear associations with other infections. This case exemplifies a rare encounter of Pseudomonas aeruginosa necrotizing pneumonia in a patient on adalimumab therapy contracted through the community. Treatment of necrotizing pneumonia in patients on adalimumab therapy does not differ significantly from other cases of non-adalimumab associated necrotizing pneumonia.